Welcome to our dedicated page for Dyadic Intl Del SEC filings (Ticker: DYAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dyadic International, Inc. (DYAI) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Dyadic, doing business as Dyadic Applied BioSolutions, is a global biotechnology company that uses proprietary C1 and Dapibus™ microbial platforms to produce recombinant, animal-free proteins and enzymes for life sciences, food and nutrition, and bio-industrial markets.
Through this page, users can review Dyadic’s Forms 10-K and 10-Q for detailed discussions of its business, risk factors, microbial expression platforms, collaborations, and financial performance. These periodic reports explain how the company generates revenue from research and development contracts, grants, licenses, milestones, and commercial activities related to its recombinant protein portfolio.
Investors can also examine Dyadic’s Form 8-K current reports, which disclose material events such as equity offerings under its shelf registration statement, Nasdaq listing deficiency notices and subsequent compliance updates, commercial agreements, corporate rebranding to Dyadic Applied BioSolutions, and strategic presentations describing its transition from R&D to commercial operations.
In addition, this page is the place to track any proxy statements and shareholder meeting results, including votes on director elections, auditor ratification, and advisory votes on executive compensation and its frequency. These filings provide insight into Dyadic’s governance practices and shareholder decisions.
Stock Titan enhances Dyadic’s filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand complex sections of 10-Ks, 10-Qs, and 8-Ks. Real-time updates from EDGAR ensure that new filings appear promptly, while structured views of ownership and transaction reports, such as Form 4 insider trading disclosures when available, allow closer monitoring of insider activity.
By combining Dyadic’s original SEC documents with AI-generated explanations, this page helps investors, researchers, and other stakeholders navigate the company’s regulatory history, capital markets actions, and evolving commercial strategy around its C1 and Dapibus™ protein production platforms.
Dyadic International, Inc. is soliciting proxies for its 2026 virtual Annual Meeting to be held on June 18, 2026. Shareholders of record as of April 24, 2026 may vote on: election of one Class I director (term to 2029); board authorization to effect a Reverse Stock Split (ratio 2:1 to 10:1); ratification of Crowe LLP as auditor; and an advisory vote on 2025 executive compensation.
There were 36,438,703 shares outstanding as of April 24, 2026. Insiders and directors beneficially own approximately 20.9%. The company disclosed $6.0M aggregate principal of 8.0% Senior Secured Convertible Notes issued March 8, 2024, with $5,090,000 principal outstanding as of the table shown.
Dyadic International, Inc. filed an amendment to its annual report for the year ended December 31, 2025 to add Part III details on directors, executive compensation, security ownership and related-party transactions. The filing describes a classified board, key executives’ backgrounds, and the company’s governance and ethics policies.
In 2025, CEO Mark Emalfarb received total compensation of $1,005,113, while President and COO Joseph Hazelton and CFO Ping Rawson received $483,337 and $413,158, respectively. The company outlines its equity incentive plans and 401(k) match. It also discloses $6.0 million in 8.0% Senior Secured Convertible Notes issued in 2024, of which $5.09 million remained outstanding as of April 24, 2026, including significant holdings by family trusts related to the CEO.
As of April 24, 2026, Dyadic had 36,438,703 common shares outstanding. CEO Mark Emalfarb beneficially owned 17.7% of common share equivalents, and The Francisco Trust beneficially owned 11.7%. The amendment also confirms independent director determinations and presents 2025 audit fees for Crowe LLP.
Dyadic International, Inc. reported that Nasdaq has notified the company it is not meeting the technical minimum requirements under Nasdaq Listing Rule 5550(b) for continued listing on the Nasdaq Capital Market. The rule requires at least $2.5 million in stockholders’ equity, $35 million in market value of listed securities, or $500,000 of net income from continuing operations.
Dyadic has 45 days, until May 11, 2026, to submit a plan to regain compliance and may receive up to 180 days from March 27, 2026 (to September 23, 2026) to cure the deficiency if Nasdaq accepts the plan. Separately, the company also remains out of compliance with Nasdaq’s $1.00 minimum bid price requirement and has until June 17, 2026 to regain compliance with that rule. Failure to cure either deficiency by the applicable deadline could lead to delisting of Dyadic’s common stock.
Dyadic Applied BioSolutions reported weaker 2025 results while advancing multiple commercial partnerships. Total revenue fell to $3.09 million from $3.50 million, mainly due to lower license and milestone revenue, partly offset by a $1.86 million increase in grant revenue from Gates Foundation and CEPI programs.
Loss from operations widened to $7.19 million, with net loss increasing to $7.36 million, or $(0.23) per share, compared with $5.81 million, or $(0.20) per share, in 2024. Cash, cash equivalents, restricted cash and investment-grade securities were about $8.6 million as of December 31, 2025. The company highlighted commercial launches and agreements across life sciences, food and nutrition, and bio-industrial markets, and scheduled an earnings call at 5:00 p.m. Eastern Time on March 25, 2026.
Dyadic International, Inc., now doing business as Dyadic Applied BioSolutions, files its annual report describing its shift from a research-focused company to a commercially oriented biotechnology business built on its proprietary C1 and Dapibus™ microbial protein production platforms.
The company targets non-therapeutic applications in life sciences, food and nutrition, and bio‑industrial markets, supported by partnerships with Proliant, Fermbox, Inzymes and BRIG BIO, and funded collaborations with groups such as the Gates Foundation and CEPI. Dyadic estimates a combined addressable market of over $25 billion across its core segments.
As of December 31, 2025, Dyadic had five full‑time employees and an accumulated deficit of about $93.5 million, with a significant share of revenue concentrated in two customers. The filing highlights extensive risk factors, including continued losses, reliance on third parties, regulatory uncertainty and intense competition from established expression systems and alternative technologies.
Dyadic International, Inc. entered into an at-the-market equity offering program that allows it to sell shares of its common stock with an aggregate offering price of up to $4,237,818 through Craig-Hallum Capital Group LLC as sales agent.
Sales can be made from time to time under an existing Form S-3 shelf and a new prospectus supplement, using methods such as ordinary broker transactions, block trades, and negotiated deals at market-related prices. Dyadic is not required to sell any shares and can suspend or terminate the program at any time. Craig-Hallum will receive up to 3.0% of the gross sales price as compensation, and Dyadic will reimburse certain expenses and provide customary indemnification.
Dyadic International, Inc. has filed a prospectus supplement to offer up to $4,237,818 of common stock in an at-the-market offering through Craig-Hallum Capital Group LLC as sales agent.
The sales agreement permits sales from time to time at prevailing market prices, with Craig-Hallum paid up to 3.0% commission. The prospectus supplement notes the public float calculation that limits sales under Form S-3 to one-third of public float and explains that Dyadic previously sold $5,749,400 in the prior 12 months, leaving an available capacity of $4,237,818 under the applicable instruction.
Dyadic International Inc. filed an amended Schedule 13G showing that Mark A. Emalfarb beneficially owns 6,675,439 shares of Dyadic common stock, representing 17.5% of the class based on 36,187,798 shares outstanding as of December 31, 2025.
The position includes 993,000 shares underlying presently exercisable options, 4,730,058 shares held through the MAE Trust, and 952,381 shares underlying an 8.0% Senior Secured Convertible Promissory Note due December 31, 2027, convertible at $1.05 per share. Emalfarb has sole voting and dispositive power over all reported shares through his role as sole trustee and beneficiary of the MAE Trust.
Dyadic International CFO Rawson Ping Wang reported equity compensation on Form 4. On January 2, 2026, Wang acquired 29,158 shares of common stock at $0, representing stock issued upon vesting of RSUs granted as a key employee annual bonus in lieu of a cash bonus earned for the year ended 2025. These RSUs vested in full upon grant, bringing Wang’s directly held common stock to 170,151 shares after the transaction.
On the same date, Wang also received an annual grant of 47,250 stock options with an exercise price of $0.94 per share. This option expires on January 2, 2036 and vests in four equal installments beginning on the first anniversary of the grant date, contingent on continued service to Dyadic International.
Dyadic International director Jack Kaye reported several equity transactions on January 2, 2026. He exercised 21,552 restricted stock units, receiving the same number of common shares at $0 per share, bringing his directly held common stock to 81,201 shares. The exercised units came from awards that vested after one year of board service and were settled fully in common stock.
On the same date, Kaye received an annual grant of 67,500 stock options with a $0.94 exercise price, exercisable starting January 2, 2027 and expiring January 2, 2036. He also received an annual grant of 39,894 restricted stock units, each representing a right to one share of common stock, scheduled to be settled entirely in shares when they vest, subject to continued board service.